Scope, Claims, and US Patent Landscape for US 11,179,328 (Aceclidine for Presbyopia and Related Visual Disturbances)
US 11,179,328 is directed to methods of treating presbyopia and specified vision complaints using an ophthalmological composition where aceclidine is the only active agent (and, in dependent claims, with formulation components such as viscosity agents and/or nonionic surfactants). The patent’s practical scope is driven less by device mechanics and more by formulation constraint (only-active-agent limitation) and therapeutic targeting (presbyopia; plus an expanded complaint list in claim 6).
What is the claim core and how is the scope constrained?
Independent claims and the “only active agent” limiter
Across the claim set you provided, the key scope gate is:
- Aceclidine is the only active agent in the ophthalmological composition.
That single phrase sharply narrows enforceable coverage versus broader claims that permit additional actives (for example, miotics, cholinergics, or multiple pharmacophores). It limits infringement risk for formulators who combine aceclidine with other pharmacologically active ingredients in the same composition.
Formulation-variable options
The independent method structure branches into three formulation “lanes”:
- Aceclidine only (no viscosity agents or surfactants called out in the independent claim set you listed)
- Aceclidine only + viscosity agent
- Aceclidine only + one or more nonionic surfactants
This architecture indicates the patent is trying to capture both:
- a baseline aceclidine eye-drop approach, and
- particular formulation vehicles that support ocular performance (residence time, spreading, tolerability, and/or comfort) through excipients rather than additional actives.
Concentration specificity appears only in the surfactant-dependent path
You provided concentration ranges (claims 4 and 5) only tied to the nonionic surfactant embodiment (claim 3). That concentration narrowing is likely intended to improve validity posture and/or distinguish prior art where aceclidine is used at different strengths or where excipient types and concentrations vary.
Claim-by-claim scope: what each claim actually covers
Claim 1
Method of treating presbyopia by administering:
- an ophthalmological composition with aceclidine as the only active agent
Scope character
- Covers any presbyopia treatment where the administered ocular composition has aceclidine as the sole active ingredient, regardless of what inactive ingredients are present, because the claim does not require viscosity agents or surfactants.
Key infringement test
- Composition must contain aceclidine and no other active agent (as construed by the patent’s “only active agent” meaning).
Claim 2
Method of treating presbyopia by administering:
- aceclidine as the only active agent and
- a viscosity agent
Scope character
- Narrows claim 1 by adding a formulation component requirement.
- Captures viscosity-modified aceclidine drops intended to improve ocular retention.
Key infringement test
- Requires a viscosity agent be present. A product with aceclidine only (claim 1 type) does not land here.
Claim 3
Method of treating presbyopia by administering:
- aceclidine as the only active agent and
- one or more nonionic surfactants
Scope character
- Narrows claim 1 to formulations with nonionic surfactants.
Key infringement test
- Surfactant must be nonionic and present in “one or more” quantities meeting the claim’s composition definition.
Claim 4
Claim 3 dependent: specifies aceclidine concentration:
Scope character
- Adds a concentration window for the nonionic surfactant embodiment.
Key infringement test
- If a presbyopia product uses aceclidine + nonionic surfactants but aceclidine is outside 0.25% to 2.5% w/v, it may avoid claim 4 while still potentially falling within claim 3.
Claim 5
Claim 3 dependent: tighter concentration:
Scope character
Key infringement test
- A product in 0.75% to 2.5% w/v with nonionic surfactants is in both claim 5 and claim 3; a product in 0.25% to 0.75% w/v with nonionic surfactants is in claim 3 and claim 4 but not claim 5.
Claim 6
A method of treating:
- low regular astigmatism
- low or high irregular astigmatism
- keratoconic ectasia
- night vision halos/starbursts
- night vision reduced contrast
- low myopia or hyperopia
- with or without astigmatism
using administration of:
- an ophthalmological composition comprising
- aceclidine as the only active agent, and
- a viscosity agent
Scope character
- Expands beyond presbyopia to a broader set of refractive and optical complaint phenotypes.
- Tethers that expanded therapeutic list to the aceclidine + viscosity agent formulation lane.
Key infringement test
- Requires both: (i) a match to at least one of the listed treated conditions/complaints and (ii) a viscosity agent.
Notable structural implication
- The patent uses the same formulation constraint (aceclidine only active + viscosity agent) to support two therapeutic domains:
- presbyopia (claim 2)
- astigmatism and night vision/refractive complaint set (claim 6)
That linkage is important for landscape mapping because it suggests the formulation approach may be the primary differentiator across multiple market indications.
How does the claim set map to possible product designs (and where design-arounds may land)?
Design path A: aceclidine-only active, no viscosity, no nonionic surfactants
- Likely targets claim 1 (presbyopia) but may avoid claims 2 and 3 if those excipients are absent.
- If nonionic surfactants are present (even with aceclidine as sole active), claim 3 is in play.
Design path B: aceclidine-only active + viscosity agent
- Likely triggers claim 2 for presbyopia and claim 6 for the expanded astigmatism/night vision/refractive set.
- If viscosity agent is present, the therapeutic indication being used becomes a central enforcement hook. Even if a clinician uses it off-label, method-of-use enforcement may hinge on what is actually marketed or practiced.
Design path C: aceclidine-only active + nonionic surfactants (with or without viscosity)
- Likely triggers claim 3 (and concentration-dependent claims 4 and 5) for presbyopia.
- If viscosity agent is also present, both claim 2 and claim 3 lanes can be asserted depending on the formulation.
Design path D: adding a second active agent
- Risk: “aceclidine as the only active agent” is designed to block co-actives.
- If a competing product includes another pharmacologically active ingredient, it is positioned to avoid literal infringement of the “only active agent” requirement, though doctrine-of-equivalents risk depends on claim construction and prosecution history not supplied here.
What is the legal “shape” of protection: method-of-treatment with formulation limitations
Type of patent protection
Based on the claims you provided, this is method-of-treatment (medical use) protection in the US system, tied to:
- treatment outcomes/indications (presbyopia; and listed refractive/night vision complaints), and
- formulation composition constraints (aceclidine as only active agent; excipient requirements such as viscosity agent or nonionic surfactants; and concentration windows in dependent claims).
Enforcement consequence
This structure tends to:
- focus infringement arguments on whether the accused product is used to treat the claimed conditions (method-use practice), and
- focus claim-literal arguments on excipient and “only active agent” composition.
It is less likely to cover a product that changes excipients or substitutes actives outside the literal boundaries of the claims.
What does this patent imply about aceclidine’s mechanism and formulation strategy?
The claim set does not describe mechanism in the text you provided, but the formulation choices are consistent with common ocular delivery objectives:
- Nonionic surfactants are typically used to stabilize formulations and improve wetting/spread.
- Viscosity agents are typically used to increase ocular contact time and reduce drainage, improving residence time.
The patent’s choice to require these excipients in specific dependent claims indicates the patentee is treating them as functional differentiators tied to therapeutic effectiveness for presbyopia and the expanded complaint set.
Where does the patent sit in the broader US drug patent landscape?
Landscape segmentation by claim differentiator
For aceclidine ocular therapies, the landscape can be segmented into three competitive clusters based on how patents often distinguish products:
-
Active ingredient monopoly vs combination formulations
- This patent’s enforceability depends on aceclidine being the only active.
-
Vehicle/excipient-driven differentiation
- Claims 2, 3, 6 and the dependent concentration constraints suggest vehicle choices are treated as patentable differentiators.
-
Indication targeting
- Presbyopia claims (1-5) and expanded complaint list (6) suggest at least two therapeutic fronts are being pursued under the same formulation theme.
Practical implication for competitors
Any competitor looking at a US product with aceclidine for ocular outcomes will typically evaluate:
- whether their formulation includes any second active, and
- whether they use viscosity agents and/or nonionic surfactants, and
- the aceclidine concentration range when nonionic surfactants are used.
Those factors map directly to the claim fence-lines you supplied.
What are the highest-value claim elements for freedom-to-operate screening?
Top infringement-sensitive elements
- “aceclidine as the only active agent”
- presence of viscosity agent (claims 2 and 6)
- presence of one or more nonionic surfactants (claims 3-5)
- aceclidine concentration window: 0.25% to 2.5% w/v and 0.75% to 2.5% w/v (claims 4-5)
- indication alignment:
- presbyopia (claims 1-5)
- specific astigmatism/keratoconus-related ectasia and night vision/refractive complaints (claim 6)
Key Takeaways
- US 11,179,328 is formulation-gated: it requires aceclidine as the only active agent in all provided claims.
- The claim set creates two principal excipient lanes: viscosity agent (claims 2 and 6) and nonionic surfactants (claims 3-5), with concentration bounds applying only to the nonionic surfactant lane.
- The therapeutic footprint is split: presbyopia (claims 1-5) and a broader astigmatism/ectasia/night vision/refractive complaint set tied to the viscosity lane (claim 6).
- For competitors, the most direct design-around levers are (i) avoiding the “only active agent” condition by using a second active, and/or (ii) removing viscosity agents or nonionic surfactants depending on which claim lane is targeted, while also controlling aceclidine strength where concentration-dependent claims are relevant.
FAQs
1) Which claims are broadest?
Claim 1 is broadest on formulation because it only requires aceclidine as the only active agent for presbyopia. Claims 2, 3, and 6 narrow scope via mandatory excipients.
2) What formulation elements most directly affect infringement risk?
The presence of a viscosity agent (claims 2 and 6) and nonionic surfactants (claims 3-5), plus whether aceclidine is the only active agent.
3) How do the concentration limits apply?
The aceclidine concentration limits (0.25% to 2.5% w/v and 0.75% to 2.5% w/v) apply only to the embodiment with nonionic surfactants (claim 3), as written in claims 4 and 5.
4) Does claim 6 cover presbyopia?
On the text you provided, claim 6 covers a different set of conditions (astigmatism/ectasia/night vision/refractive complaints) and does not list presbyopia. Coverage depends on whether the treated condition matches that list.
5) What is the most effective design-around direction implied by the claims?
The strongest implied control point is the “only active agent” limitation. Second-order design-around levers are removing required excipients (viscosity agent or nonionic surfactants) depending on which claim lane is at issue.
References
[1] US Patent 11,179,328 (claims provided by user).
